Drug news
Relday from Zogenix is filed at FDA for Schizophrenia
Zogenix has submitted an investigational new drug application to the FDA for Relday, which is a combination of Zogenix's DosePro needle-free, subcutaneous drug delivery system plus a proprietary, subcutaneous once-monthly formulation of risperidone for treating Schizophrenia.If approved, Relday will be the first subcutaneous, needle-free antipsychotic product that allows for once-monthly dosing. Zogenix believes that Relday will offer an improved pharmacokinetic profile, significant reduction in injection volume and a simplified dosing regimen due to the SABER controlled-release formulation technology from Durect in combination with Zogenix's DosePro needle-free subcutaneous drug delivery system.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins